Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of dabrafenib + trametinib in pediatric BRAF V600-mutant low-grade or high-grade glioma
MOH_2019-10-15_007446Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dabrafenib + trametinib and trametinib in glioma (3 arms), sponsored by Novartis. Started Jun 2019; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
glioma
Beyond the preview
Go deeper on MOH_2019-10-15_007446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-15_007446.